Health
Study examines efficacy of Pfizer-BioNTech mRNA COVID-19 vaccine across demographic groups – News-Medical.Net
A new study examines data from Israel’s vaccination campaign to assess the efficacy of the Pfizer-BioNTech mRNA vaccine across different demographics.
Scientists across the world are racing against time to develop effective vaccines for severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) to contain the current coronavirus disease 2019 (COVID-19) pandemic. The phase III trial of the mRNA-based BNT162b2 COVID-19 vaccine showed 95% efficacy in preventing SARS-COV-2 infection. In this randomized placebo-controlled trial, the vaccine was found to be effective 12 days following the first dose. Despite several advantages of a controlled trial,…
-
Business20 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business19 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Business16 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News16 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred